BioWorld - Tuesday, October 28, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » Novel c-Myc inhibitor shows preclinical ...
--First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver -- --Data shows ...
Hosted on MSN
Omomyc enhances PARP inhibitor effects and overcomes resistance in breast cancer models
Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a phase I clinical trial—causes DNA damage in cancer cells which is ...
Melanomas resistant to BRAF inhibitors show increased polyamine biosynthesis, driven by the activation of the oncogene c-Myc. This ultimately leads to increased mitochondrial activity and drug ...
Investigators at West China Hospital, Sichuan University and affiliated organizations have discovered a novel c-Myc inhibitor being developed as a potential anticancer agent.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results